Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Hard-to-Treat prostate cancer: targeted drug TD001 enters human trials

NCT ID NCT07258407

Recruiting now Disease control Sponsor: T.O.A.D. Oncology SA Source: ClinicalTrials.gov ↗

First seen Jan 08, 2026 · Last updated Apr 26, 2026 · Updated 14 times

Summary

This study tests a new drug called TD001 in men with a type of advanced prostate cancer that has stopped responding to hormone therapy. The drug is designed to seek out and attack cancer cells that have a specific marker (PSMA) on their surface. The main goals are to find the safest dose and to see if the drug can shrink tumors or slow the disease. About 180 participants will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hôpital Paris Saint Joseph

    RECRUITING

    Paris, 75014, France

  • Institut Bergonié

    RECRUITING

    Bordeaux, 33076, France

  • Institut Gustave Roussy

    RECRUITING

    Villejuif, 94805, France

  • Yale University, Yale Cancer Center

    NOT_YET_RECRUITING

    New Haven, Connecticut, 06520, United States

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATIC CANCER